Filing Analysis
Regulation FD Disclosure
Filed May 06, 2026
LOW
TScan Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the filing.
Key Facts
- The company reported financial results for the quarter ended March 31, 2026.
- The report was filed on May 6, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The press release containing the detailed financial data was furnished as Exhibit 99.1.
Officer Departure
Filed Apr 02, 2026
MEDIUM
TScan Therapeutics announced the resignation of Leiden Dworak, Vice President of Finance and Principal Accounting Officer, effective April 10, 2026. The Company's current CFO, Jason A. Amello, will assume the additional role of Principal Accounting Officer.
Key Facts
- Leiden Dworak notified the company of his resignation on March 31, 2026.
- The resignation is effective April 10, 2026.
- Jason A. Amello (CFO) is appointed as the Principal Accounting Officer effective April 10, 2026.
- The company stated there were no disagreements regarding operations, policies, or practices.
- Mr. Amello will receive no additional compensation for the added responsibilities.
Other SEC Filing
Filed Mar 04, 2026
LOW
TScan Therapeutics announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The results were released via a press release furnished with the filing.
Key Facts
- Financial results cover Q4 2025 and the full fiscal year ended December 31, 2025.
- The press release is furnished as Exhibit 99.1.
- The report was signed by CEO Gavin MacBeath, Ph.D. on March 4, 2026.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.